Fox Run Management L.L.C. Invests $588,000 in Edwards Lifesciences Corp (EW) Stock

Fox Run Management L.L.C. bought a new stake in Edwards Lifesciences Corp (NYSE:EW) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 4,039 shares of the medical research company’s stock, valued at approximately $588,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Wendell David Associates Inc. raised its stake in Edwards Lifesciences by 4.0% in the 2nd quarter. Wendell David Associates Inc. now owns 9,548 shares of the medical research company’s stock valued at $1,390,000 after purchasing an additional 363 shares during the last quarter. IHT Wealth Management LLC grew its holdings in Edwards Lifesciences by 84.6% in the 1st quarter. IHT Wealth Management LLC now owns 932 shares of the medical research company’s stock valued at $126,000 after buying an additional 427 shares during the period. Gulf International Bank UK Ltd grew its holdings in Edwards Lifesciences by 0.7% in the 1st quarter. Gulf International Bank UK Ltd now owns 66,330 shares of the medical research company’s stock valued at $9,254,000 after buying an additional 450 shares during the period. Daiwa Securities Group Inc. grew its holdings in Edwards Lifesciences by 9.1% in the 1st quarter. Daiwa Securities Group Inc. now owns 6,891 shares of the medical research company’s stock valued at $961,000 after buying an additional 572 shares during the period. Finally, WealthPLAN Partners LLC grew its holdings in Edwards Lifesciences by 22.2% in the 1st quarter. WealthPLAN Partners LLC now owns 3,225 shares of the medical research company’s stock valued at $450,000 after buying an additional 585 shares during the period. 81.27% of the stock is owned by hedge funds and other institutional investors.

Get Edwards Lifesciences alerts:

Several analysts have commented on EW shares. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Saturday, July 14th. ValuEngine upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Tuesday, June 12th. SunTrust Banks restated a “buy” rating and issued a $180.00 price target on shares of Edwards Lifesciences in a report on Tuesday, April 10th. Sanford C. Bernstein started coverage on Edwards Lifesciences in a report on Wednesday, June 27th. They issued a “market perform” rating and a $165.00 price target for the company. Finally, Northland Securities cut Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 25th. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $152.65.

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 9th. The stock was sold at an average price of $134.73, for a total value of $3,368,250.00. Following the completion of the transaction, the chief financial officer now owns 35,968 shares in the company, valued at approximately $4,845,968.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,800 shares of the company’s stock in a transaction that occurred on Monday, April 30th. The stock was sold at an average price of $128.46, for a total value of $4,213,488.00. Following the completion of the transaction, the chief executive officer now owns 74,131 shares of the company’s stock, valued at approximately $9,522,868.26. The disclosure for this sale can be found here. Insiders have sold a total of 230,249 shares of company stock valued at $31,802,645 in the last quarter. Company insiders own 1.84% of the company’s stock.

Shares of NYSE:EW opened at $152.62 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.07 and a quick ratio of 1.63. Edwards Lifesciences Corp has a 1 year low of $100.20 and a 1 year high of $155.22. The stock has a market cap of $31.68 billion, a PE ratio of 36.83, a PEG ratio of 2.20 and a beta of 0.64.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, April 24th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.11. Edwards Lifesciences had a return on equity of 28.60% and a net margin of 17.36%. The business had revenue of $938.00 million during the quarter, compared to analysts’ expectations of $936.69 million. During the same quarter in the previous year, the business earned $0.94 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. sell-side analysts forecast that Edwards Lifesciences Corp will post 4.63 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Recommended Story: Understanding Price to Earnings Ratio (PE)

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).